How efficacious and safe is short-acting methylphenidate for the treatment of attention-deficit disorder in children and adolescents? A meta-analysis

Schachter, Howard M.; Pham, Ba'; King, Jim; Langford, Stephanie; Moher, David
November 2001
CMAJ: Canadian Medical Association Journal;11/27/2001, Vol. 165 Issue 11, p1475
Academic Journal
Abstract Background Numerous small clinical trials have been carried out to study the behaviourally defined efficacy and safety of short-acting methylphenidate compared with placebo for attention-deficit disorder (ADD) in individuals aged 18 years and less. However, no meta-analyses that carefully examined these questions have been done. We reviewed the behavioural evidence from all the randomized controlled trials that compared methylphenidate and placebo, and completed a meta-analysis. Methods We searched several electronic sources for articles published between 1981 and 1999: MEDLINE, EMBASE, PsychINFO, ERIC, CINAHL, HEALTHSTAR, Biological Abstracts, Current Contents and Dissertation Abstracts. The Cochrane Library Trials Registry and Current Controlled Trials were also consulted. A study was considered eligible for inclusion if it entailed the following: a placebo- controlled randomized trial that involved short-acting methylphenidate and participants aged 18 years or less at the start of the trial who had received any primary diagnosis of ADD that was made in a systematic and reproducible way. Results We included 62 randomized trials that involved a total of 2897 participants with a primary diagnosis of ADD (e.g., with or without hyperactivity). The median age of trial participants was 8.7 years, and the median "percent male" composition of trials was 88.1%. Most studies used a crossover design. Using the scores from 2 separate indices, this collection of trials exhibited low quality. Interventions lasted, on average, 3 weeks, with no trial lasting longer than 28 weeks. Each primary outcome (hyperactivity index) demonstrated a significant effect of methylphenidate (effect size reported by teacher 0.78, 95% confidence interval [CI] 0.64-0.91; effect size reported by parent 0.54, 95% CI 0.40-0.67). However, these apparent beneficial effects are tempered by a strong indication of publication bias and the lack of robustness of the findings, especially tho...


Related Articles

  • DRAWING THE LINE. Rogers, Patrick // People;7/23/2001, Vol. 56 Issue 4, p50 

    Discusses the controversy of giving the drug Ritalin to children, for the treatment of attention-deficit/hyperactivity disorder (ADHD).

  • ADHD Update.  // PharmaWatch: CNS;Dec2011, Vol. 10 Issue 12, p15 

    The article reports on the positive results presented by Shire PLC from its European Phase III research of once-daily lisdexamfetamine dimesylate (LDX) in adolescents and children aged six-17 with attention-deficit/hyperactivity disorder (ADHD). It states that LDX is a long-acting, prodrug of...

  • Study Points to Academic Benefits for Adolescents Taking Ritalin. Viadero, Debra // Education Week;06/06/2001, Vol. 20 Issue 39, p10 

    Reports on the study published in the journal 'Experimental & Clinical Psychopharmacology' on the effects of Ritalin on teenagers with attention deficit hyperactivity disorder in the United States. Effect of the drug on students' academic performance when used in combination with other...

  • Drugs in Clinical Development for Attention-Deficit/Hyperactivity Disorder: Summary and Table.  // Pharmaceutical Medicine - New Zealand;2013, Vol. 27 Issue 4, p245 

    The article discusses the clinical development of drugs for attention-deficit/hyperactivity disorder (ADHD). It mentions the phase II/III development of oral selective noradrenergic reuptake inhibitor (SNRI) edivoxetine for ADHD in children. Clinical trial is conducted on serotonin,...

  • Seguridad y eficacia de la atomoxetina en niños con trastorno por déficit de atención/hiperactividad (TDAH): fase inicial durante 10 semanas en estudio de prevención de recaídas en una muestra española.  // Actas Espanolas de Psiquiatria;ene2005, Vol. 33 Issue 1, p26 

    INTRODUCTION: Attention-deficit/hyperactivity disorder (ADHD) appears to be associated to problems with regulation of cortical dopaminergic/noradrenergic function. The purpose of this work is to present efficacy and safety data from 10-week open label treatment with atomoxetine, a highly...

  • ADHD in Juvenile Offenders. Shelton, Deborah; Pearson, Geraldine // Journal of Psychosocial Nursing & Mental Health Services;Sep2005, Vol. 43 Issue 9, p38 

    The article discusses the attention-deficit/hyperactivity disorder (ADHD) among children and adolescents with focus on treatment information for nurses. Children with ADHD are at risk for involvement with the juvenile courts. A coordinated effort among clients and their families, health care...

  • Pemoline (Cylert) in the Treatment of Childhood Hyperkinesis. Page, John G.; Janicki, Robert S.; Bernstein, Joel E.; Curran, Charles F.; Michelli, Frank A. // Journal of Learning Disabilities;Oct1974, Vol. 7 Issue 8, p498 

    A controlled, double-blind study using pemoliqe and placebo in the management of hyper-kinetic behavior associated with minimal brain dysfunction is described. Improvement in gross behavior as measured by parent, teacher and physician global evaluations, as well as improvement in cognitive and...

  • Metilfenidato en niños y adolescentes con déficit de atención e hiperactividad: estudio DIHANA. Usón, J. R. Valdizán // Acta Pediátrica Española;mar2013, Vol. 71 Issue 3, p67 

    Introduction: Attention deficit/hyperactivity disorder (ADHD) affects a significant proportion of the child and adolescent population. Aim: This study focuses on determining the response to immediate- release methylphenidate in children and adolescents diagnosed with ADHD, as well as obtaining...

  • The Homeopathic Treatment of Attention Deficit Disorders. Ullman, Dana // Latitudes;2002, Vol. 5 Issue 4, p20 

    Discusses the effectiveness of homeopathic treatment for children with Attention Deficit Disorders (ADD). Short-term side effects associated with drug ritalin used for treating children with ADD; Prescription of homeopathic medicine on individual basis; Comparison of homeopathic treatment with...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics